Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
21:38:51 EDT Sun 28 Apr 2024
Enter Symbol
or Name
USA
CA



News for U:CANF from 2023-04-27 to 2024-04-26 - 33 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-25 07:00U:CANFNews ReleaseLong-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal
2024-04-15 07:00U:CANFNews ReleaseCan-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH
2024-04-03 07:00U:CANFNews ReleaseCan-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients
2024-04-01 07:01U:CANFNews ReleaseCan-Fite BioPharma, Ltd. to Present at the LD Micro Invitational XIV
2024-03-28 07:00U:CANFNews ReleaseCan-Fite Reports 2023 Financial Results and Clinical Update
2024-03-11 07:00U:CANFNews ReleaseNamodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference
2024-02-28 07:00U:CANFNews ReleaseCan-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada
2024-01-30 07:00U:CANFNews ReleaseCan-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication
2024-01-29 07:00U:CANFNews ReleaseCan-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis Study
2023-12-20 07:00U:CANFNews ReleaseThe Anti-Obesity Effect of Can-Fite ¢ € ™s Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studies
2023-12-18 07:00U:CANFNews ReleaseCan-Fite Received FDA Positive Response to Psoriasis Pediatric Plan
2023-12-04 07:00U:CANFNews ReleaseCan-Fite ¢ € ™s Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical Development
2023-11-30 07:00U:CANFNews ReleaseCan-Fite Reports Third Quarter 2023 Financial Results and Clinical Update
2023-11-21 13:53U:CANFNews ReleaseCan-Fite Announces Exercise of Warrants for Approximately $3.0 Million in Gross Proceeds
2023-11-21 07:00U:CANFNews ReleaseCan-Fite: Complete Response and 6.9 Years ‚  Overall Survival in a Patient with Advanced Liver Cancer Treated with Namodenoson
2023-11-01 07:00U:CANFNews ReleaseCan-Fite Issues Business Update: All Clinical Programs and Business Development Activities Remain Solidly on Track
2023-10-30 07:00U:CANFNews ReleaseCan Fite: Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal; Robust anti-Cancer Effect & Molecular Mechanism of Action
2023-10-26 07:00U:CANFNews ReleaseCan-Fite to Harness Artificial Intelligence to Develop Novel Anti-Cancer Drugs
2023-10-09 07:00U:CANFNews ReleaseCan-Fite to Share its Rare Genetic Disease Lowe Syndrome Novel Treatment with Orphan Drug Japanese Companies
2023-09-27 07:00U:CANFNews ReleaseCan-Fite Novel Approach for the Treatment of Pancreatic Carcinoma with Namodenoson Receives Appreciation of the American Association of Cancer Research (AACR)
2023-09-07 07:00U:CANFNews ReleaseCan-Fite to Share with Investors Latest Oncology and Rare Genetic Disease Developments at the H.C. Wainwright 25th Annual Conference
2023-08-31 07:00U:CANFNews ReleaseCan-Fite Reports Second Quarter 2023 Financial Results & Progress in Two Pivotal Phase III Clinical Studies
2023-08-24 07:10U:CANFNews ReleaseCan-Fite Enters Rare Genetic Disease Field Based on impactful findings of a Fondazione Telethon and Naples University Researcher showing Piclidenoson is efficacious in Treating Lowe Syndrome
2023-08-18 07:00U:CANFNews ReleaseCan-Fite Submitted to FDA a Pediatric Plan to Allow Registration of Piclidenoson for the Treatment of Adolescents with Psoriasis
2023-07-17 07:00U:CANFNews ReleaseCan-Fite: Granted Breakthrough Abstract Award for Namodenoson in Treatment of Advanced Liver Cancer by ASCO Conquer Cancer Foundation
2023-06-29 07:00U:CANFNews ReleaseCan-Fite Receives U.S. FDA ¢ € ™s Go Ahead for Piclidenoson Psoriasis Registration Plan
2023-06-13 07:00U:CANFNews ReleaseCan-Fite to Submit IND for the Treatment of Pancreatic Cancer Patients with Namodenoson
2023-06-02 07:00U:CANFNews ReleaseCan-Fite to Participate in Out-licensing and Distribution Partnering Meetings at Bio International Convention in Boston
2023-06-01 07:00U:CANFNews ReleaseCan-Fite Reports First Quarter 2023 Financial Results & Provides Clinical Update
2023-05-30 07:00U:CANFNews ReleaseCan-Fite: Namodenoson ¢ € ™s Inhibition of Pancreatic Carcinoma Receives Recognition from the American Society of Clinical Oncology (ASCO)
2023-05-15 07:00U:CANFNews ReleaseCan-Fite: Presenting Namodenoson ¢ € ™s New Pancreatic Cancer Indication to Potential Partners at BioEquity Europe 2023
2023-05-09 07:00U:CANFNews ReleaseCan-Fite to Initiate Exploratory Phase 2 Trial with Namodenoson in Pancreatic Cancer Patients
2023-05-02 07:00U:CANFNews ReleaseInhibition of Pancreatic Cancer by Namodenoson: Molecular Mechanism of Action Discovered by Can-Fite Scientists